Abstracts tagged "outcomes and rheumatoid arthritis (RA)"

Abstract Number: 277 • 2018 ACR/ARHP Annual Meeting
Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Elizabeth Ferucci¹, Tammy Choromanski¹, Gretchen Day² and Sarah Freeman³, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Clinical and Research Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Telehealth, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: In rheumatoid arthritis (RA), access to a rheumatologist is associated with improved quality of care and outcomes. Telemedicine has been proposed as a solution…
Abstract Number: 484 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Have Lower Preoperative Expectations but Greater Clinical Improvement after Total Knee Arthroplasty Compared to Osteoarthritis Patients
Jason Blevins¹, Yu-fen Chiu², Stephen Lyman³, Susan M. Goodman¹, Lisa A. Mandl⁴, Peter K. Sculco⁵, Mark P. Figgie⁶ and Alexander McLawhorn², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, new york, NY, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Preoperative patient expectations of Total Knee Arthroplasty (TKA) influence postoperative outcomes and satisfaction. Rheumatoid Arthritis (RA) may lower preoperative expectations after TKA compared to…
Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Kathy Cui¹, Mohammad Movahedi², Claire Bombardier³ and Bindee Kuriya^4,5,6, ¹Western University, London Health Sciences Centre, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…
Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Renaud Felten¹, Marie-Alexandra Alyanakian², Lucienne Chatenoud², Jean Sibilia¹, Frédérique Gandjbakhch³, Cédric Lukas⁴ and Jacques-Eric Gottenberg¹, ¹University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, ²Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, ³Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, ⁴University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
Abstract Number: 1462 • 2018 ACR/ARHP Annual Meeting
Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness
Dana Orange¹, Caroline Jiang¹, Edward F. DiCarlo², Tania Pannellini³, Laura T. Donlin⁴, Serene Z. Mirza⁵, Mark P. Figgie⁶, Vivian P. Bykerk⁷, Ana-Maria Orbai⁸, Sarah Mackie⁹ and Susan M. Goodman³, ¹Rockefeller University, New York, NY, ²Laboratory Medicine, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Surgery, Hospital for Special Surgery, New York, NY, ⁷Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Stiffness is a hallmark of RA, but little is known about the etiology. We investigated stiffness association with RA disease activity and determined whether…
Abstract Number: 2492 • 2018 ACR/ARHP Annual Meeting
Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Chun Li², Jing Yang³, Hua Wei⁴, Jianlin Huang⁵, Wenqiang Fan⁶, Yongfu Wang⁷, Hongzhi Wang⁸, Jinmei Zou³, Xiaofei Shi⁹, Xiafei Xin¹⁰, Jianhong Wu¹¹, Fen Li¹², Shouxin Li¹³, Huiqin Yang¹⁴, Anbing Zhang¹⁵, Dongbao Zhao¹⁶, Jinchang He¹⁷, Junli Zhang¹⁸, Luo Li¹⁹, Peng Ji²⁰, Xiaofeng Rong²¹, Feng Jiang²², Ling Wang²³, Yuhua Jia²⁴, Fei Xiao²⁴ and Zhan-Guo Li²⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Northern Jiangsu People's Hospital, Yangzhou, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁷The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁸The First Hospital of Jiaxing, Jiaxing, China, ⁹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁰Ningbo First Hospital, Zhejiang, Ningbo, China, ¹¹Dazhou Central Hospital, Dazhou, China, ¹²The Second Xiangya Hospital of Central South University, Changsha, China, ¹³Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ¹⁴Wuhan No 1 Hospital, wuhan, China, ¹⁵Xiangyang Central Hospital, Xiangyang, China, ¹⁶Changhai Hospital of Shanghai, Shanghai, China, ¹⁷PanZhiHua Central Hospital, Panzhihua, China, ¹⁸Xi 'an no.5 hospital, Xian, China, ¹⁹The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ²⁰[email protected], Wulumuqi, China, ²¹Affiliated hospital of Chongqing medical University, Chongqing, China, ²²Huzhou Third People's Hospital, Huzhou, China, ²³Zao Zhuang Municipal Hospital, zaozhuang, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 score lower than 2.6 (remission, Rem) or below 3.2 (low disease activity, LDA), is the main management strategy recommended…
Abstract Number: 128 • 2017 ACR/ARHP Annual Meeting
Use of Machine Learning and Traditional Statistical Methods to Classify RA-Related Disability Using Administrative Claims Data
Jeffrey R. Curtis¹, Huifeng Yun², Carol J. Etzel³, Shuo Yang⁴ and Lang Chen⁴, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Administrative claims and electronic health record (EHR) data are commonly used to assess outcomes in rheumatoid arthritis (RA). However, direct measures of functional status…
Abstract Number: 442 • 2017 ACR/ARHP Annual Meeting
Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis
Franchesca Cruz-Pérez¹, Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez², Naydi Pérez-Ríos³, Noelia Rodríguez-Pérez¹, Grissel Ríos⁴ and Luis M. Vilá⁵, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁴Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) has a disease-modifying effect in rheumatoid arthritis (RA) patients but also it is associated with improved lipid profile, and decreased risk for…
Abstract Number: 469 • 2017 ACR/ARHP Annual Meeting
Effect of Patient Involvement in Treatment Decision Making on Disease Outcomes in Rheumatoid Arthritis in the USA
Richard Hutchings¹, Shailja Panchal² and Elizabeth Baynton¹, ¹Ipsos Healthcare, London, United Kingdom, ²Ipsos Healthcare, New York, NY
Background/Purpose: ACR guidelines for treating Rheumatoid Arthritis (2015) suggest that treatment decisions should be made by physicians and patients through a shared decision-making process taking…
Abstract Number: 1054 • 2017 ACR/ARHP Annual Meeting
Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Nina Mars^1,2, Anne M Kerola^2,3, Markku J Kauppi^4,5, Matti Pirinen¹, Outi Elonheimo⁶ and Tuulikki Sokka-Isler⁷, ¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore…
Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting
Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
Keith Knapp^1,2, Eric Mueller^1,2 and Gary Craig^1,2, ¹Arthritis Northwest PLLC., Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
Abstract Number: 1384 • 2017 ACR/ARHP Annual Meeting
Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All over the Map!
Matthew Turk¹ and Janet E. Pope², ¹Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: Assessments of disease activity in rheumatoid arthritis (RA) determine the course of treatment. Physician global assessments of disease activity (MD globals) are important outcomes…
Abstract Number: 2861 • 2017 ACR/ARHP Annual Meeting
Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
Vibeke Norvang¹, Inge C Olsen², Joseph Sexton¹, Eirik K Kristianslund¹, Till Uhlig¹, Tore Kvien³, Daniel Aletaha⁴, Josef S. Smolen⁴ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose : In a treat-to-target strategy in rheumatoid arthritis (RA) treatment adoptions are recommended in case of poor improvement in disease activity 3 months after…
Abstract Number: 2468 • 2016 ACR/ARHP Annual Meeting
Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis
Nashla Barroso¹, Thasia G Woodworth², Francis Guillemin³, Daniel E. Furst⁴, Jenny Brook⁵, Suzanne Kafaja⁶, David Elashoff⁵, Bruno Fautrel⁷ and Veena Ranganath⁸, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Leading Edge Clinical Research, Stuart, FL, ³CHRU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Medicine, David Geffen School of Medicine, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ⁸Cumberland Valley Rheumatology, P.C., Chambersburg, PA
Background/Purpose: Due to the lack of consensus of the definition of a rheumatoid arthritis (RA) flare, the French “FLARE” (FLare Assessment in RA) instrument was…
Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting
Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Cecilie Heegaard Brahe¹, Simon Krabbe², Mikkel Østergaard³, Henrik Rogind⁴, Hanne Slott Jensen³, Annette Hansen⁵, Jesper Nørregaard⁶, Søren Jacobsen⁷, Lene Terslev⁸, Tuan K. Huynh⁹, Dorte Vendelbo Jensen⁵, Natalia Manilo¹⁰, Karsten Heller Asmussen¹¹, Per Brown-Frandsen⁷, Mikael Boesen¹², Zoreh Rastiemadabadi¹³, Daniel Glinatsi¹⁴, Lone Morsel-Carlsen¹⁵, Jakob M. Møller¹⁶, Niels Steen Krogh¹⁷ and Merete Lund Hetland^3,18, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, ¹⁰The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹¹Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, ¹²Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark, ¹³Department of Radiology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁴Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ¹⁵Department of Radiology, Rigshospitalet, Copenhagen, Denmark, ¹⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ¹⁷Zitelab, Frederiksberg, Denmark, ¹⁸Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].